Digital Vocal Biomarkers

For remote clinical trial monitoring in Huntington's Disease (HD) drug discovery

 

Canary Speech is setting a new standard for diagnostic evaluation within clinical drug discovery.

 

Our revolutionary technology processes vocal biomarkers to track the presence and severity of diseases such as Huntington's Disease, anxiety and depression. After just 40 seconds of conversational speech, Canary delivers objective and real-time results. Diagnostic insights are multiplied through longitudinal tracking and measurement, improving patient outcomes and giving a comprehensive view to healthcare professionals.

 

SCALEABLE

  • Used in virtual care and clinical settings

NON-INVASIVE

  • Individual engages on any smart device with real-time analysis

COST EFFICIENT

  • SaaS model with low monthly user fee

INNOVATIVE

  • Unlocks disruptive speed of capture and analysis of actionable data for clinical teams

Huntingtons Infographic (1)-1
Untitled (2000 × 2000 px) (4)

Research

A partnership between Beth Israel Deaconess Medical Center and Canary Speech has resulted in two compelling studies, "Automated Audio Analysis of Dysarthria in Huntington’s disease," and "Detecting Manifest Huntington's Disease Using Voice Data." Together, they successfully detected speech changes in patients of Huntington’s disease.

Untitled (2000 × 2000 px) (2)

Press

The Neuro Rehab Times spoke to CEO and co-founder Henry O’Connell about using Canary Speech's technology in early identification and neuro rehab for diseases such as Parkinson's, Huntington's, and Alzheimer's Disease. Read the article  "How voice AI will change neuro diagnosis" to learn more.

Untitled (2000 × 2000 px) (3)

Poster Presentation

The Beth Israel Deaconess Medical Center team identified the features of speech that differentiate HD from controls using Canary Speech's technology. Identified features have been integrated into learning models to generate speech biomarkers with the highest sensitivity for early changes in HD. View the poster presented at the 2022 Huntington Study Group.

1-2

Want more info?

Get in touch today.

 

Caitlyn@canaryspeech.com

canaryspeech.com